We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DE:NYSEDeere & Company Analysis

Data as of 2026-05-19 - not real-time

$564.49

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Deere & Company is trading at $564.49, well above its DCF-derived fair value of $55, giving it a clear overvaluation signal. The stock’s forward P/E of 24.5 and current P/E of 31.9 sit above the industry average of 29.5, while the dividend yield of 1.15% and a modest payout ratio of 36% suggest earnings can comfortably support the payout. Technicals are mixed: the 20‑day SMA (577) and 50‑day SMA (580) sit above price, the RSI is neutral at 44, and the MACD histogram is bearish, indicating short‑term downside pressure toward the $555 support level. Recent material news includes the appointment of Brent Norwood as CFO, signaling strategic focus on acquisitions and digital agriculture, and a short‑term price boost from falling oil prices that lowered input‑cost pressures.
Despite a high debt‑to‑equity ratio of 376 and a 30‑day volatility of 35%, the stock benefits from a low beta (0.58), stable volume, and a solid dividend. The company’s revenue is down 11% YoY, but operating margins remain healthy at 17.5% and forward earnings guidance is being raised, pointing to a potential earnings recovery that could narrow the valuation gap over the medium horizon.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and proximity to $555 support
  • Recent CFO appointment adds strategic uncertainty
  • Stable volume but high valuation gap

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward earnings growth and raised guidance
  • Dividend yield with sustainable payout
  • Strategic focus on precision agriculture and digital tools

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Secular demand for agricultural and construction equipment
  • High leverage and revenue contraction risk
  • Strong brand and dividend track record

Key Metrics & Analysis

Financial Health

Revenue Growth-11.10%
Profit Margin10.30%
P/E Ratio31.9
ROE19.57%
ROA3.96%
Debt/Equity376.02
P/B Ratio5.8
Op. Cash Flow$7.7B
Free Cash Flow$4.2B
Industry P/E29.5

Technical Analysis

TrendNeutral
RSI43.8
Support$555.56
Resistance$598.66
MA 20$577.07
MA 50$580.15
MA 200$519.93
MACDBearish
VolumeStable
Fear & Greed Index89.21

Valuation

Fair Value$55.02
Target Price$665.10
Upside/Downside17.82%
GradeOvervalued
TypeBlend
Dividend Yield1.15%

Risk Assessment

Beta0.58
Volatility35.69%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.